Moderna, Inc.

Jun 18, 2026 4:00pm ET Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine by ACCESS Newswire Jun 17, 2026 7:00am ET Moderna to Host Investor Event - Science Day by ACCESS Newswire Jun 16, 2026 7:30am ET Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028 by ACCESS Newswire Jun 08, 2026 7:01pm ET Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome by ACCESS Newswire Jun 02, 2026 7:00am ET Moderna to Present at Upcoming Conference in June 2026 by ACCESS Newswire Jun 01, 2026 8:00am ET Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting by ACCESS Newswire Jun 01, 2026 5:00am ET Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus by ACCESS Newswire May 12, 2026 5:00pm ET Moderna Recognized by TIME as One of the World's Most Impactful Companies by ACCESS Newswire May 06, 2026 5:15pm ET Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 by ACCESS Newswire May 01, 2026 6:30am ET Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates by ACCESS Newswire Apr 21, 2026 7:01pm ET Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate by ACCESS Newswire Apr 21, 2026 10:00am ET Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting by ACCESS Newswire Apr 21, 2026 9:40am ET Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 by ACCESS Newswire Apr 21, 2026 7:00am ET Moderna to Present at Upcoming Conferences in May 2026 by ACCESS Newswire Apr 17, 2026 3:00pm ET Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting by ACCESS Newswire Apr 15, 2026 7:00am ET Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026 by ACCESS Newswire Apr 06, 2026 6:01pm ET Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 by ACCESS Newswire Mar 03, 2026 4:15pm ET Moderna Resolves Global Patent Litigation with Arbutus/Genevant by ACCESS Newswire Feb 27, 2026 7:00am ET European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 by ACCESS Newswire Feb 19, 2026 7:00am ET Moderna to Present at Upcoming Conferences in March 2026 by ACCESS Newswire Feb 18, 2026 7:00am ET Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission by ACCESS Newswire Feb 17, 2026 7:00am ET Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE by ACCESS Newswire Feb 13, 2026 7:00am ET Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates by ACCESS Newswire Feb 11, 2026 10:46am ET Moderna Stock Alert: - Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Moderna Investors - MRNA by Newsfile Feb 10, 2026 6:00pm ET Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 by ACCESS Newswire Feb 10, 2026 7:00am ET Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico by ACCESS Newswire Jan 30, 2026 7:30am ET Dr. David Berman to Join Moderna as Chief Development Officer by ACCESS Newswire Jan 29, 2026 5:00pm ET Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927) by ACCESS Newswire Jan 26, 2026 7:00am ET Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026 by ACCESS Newswire Jan 20, 2026 6:00am ET Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection by ACCESS Newswire Jan 12, 2026 7:00am ET Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference by ACCESS Newswire Jan 05, 2026 7:00am ET Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine by ACCESS Newswire Dec 18, 2025 7:00am ET CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate by ACCESS Newswire Dec 17, 2025 7:00am ET Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference by ACCESS Newswire Dec 15, 2025 7:00am ET EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) by ACCESS Newswire Nov 20, 2025 7:00am ET Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates by ACCESS Newswire Nov 20, 2025 7:00am ET Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management by ACCESS Newswire Nov 19, 2025 7:00am ET Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities by ACCESS Newswire Nov 18, 2025 7:00am ET Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025 by ACCESS Newswire Nov 06, 2025 7:00am ET Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates by ACCESS Newswire Nov 03, 2025 7:00am ET Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma by ACCESS Newswire Oct 23, 2025 2:42pm ET Moderna Named a Top Employer by Science for Eleventh Consecutive Year by ACCESS Newswire Oct 23, 2025 7:00am ET Moderna to Host Investor Event - Analyst Day by ACCESS Newswire Oct 22, 2025 4:05pm ET Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint by ACCESS Newswire Oct 19, 2025 8:00am ET Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 by ACCESS Newswire Oct 16, 2025 7:00am ET Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 by ACCESS Newswire Oct 12, 2025 6:05pm ET Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress by ACCESS Newswire Sep 24, 2025 7:01pm ET Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK by ACCESS Newswire Sep 23, 2025 7:00am ET Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans by ACCESS Newswire Sep 19, 2025 3:10pm ET Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories by ACCESS Newswire Sep 16, 2025 6:00am ET Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans by ACCESS Newswire Sep 02, 2025 7:00am ET Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism by ACCESS Newswire Aug 27, 2025 1:24pm ET Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 by ACCESS Newswire Aug 22, 2025 9:25am ET Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 by ACCESS Newswire Aug 21, 2025 7:00am ET Moderna to Present at Upcoming Conferences in September 2025 by ACCESS Newswire Aug 01, 2025 7:00am ET Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates by ACCESS Newswire Aug 01, 2025 6:00am ET UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech by ACCESS Newswire Jul 30, 2025 4:05pm ET Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 by ACCESS Newswire Jul 28, 2025 7:00am ET Moderna Announces Data to be Presented at ESMO Congress 2025 by ACCESS Newswire Jul 25, 2025 8:45am ET EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1 by ACCESS Newswire Jul 11, 2025 7:00am ET Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025 by ACCESS Newswire Jul 10, 2025 8:00am ET Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease by ACCESS Newswire Jun 30, 2025 7:00am ET Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine by ACCESS Newswire Jun 12, 2025 7:25pm ET Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease by ACCESS Newswire Jun 11, 2025 7:00am ET Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 by ACCESS Newswire May 31, 2025 12:16am ET Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE by ACCESS Newswire May 28, 2025 6:00pm ET Moderna Announces Update on Investigational Pandemic Influenza Program by ACCESS Newswire May 27, 2025 7:00am ET Moderna to Present at Upcoming Conferences in June 2025 by ACCESS Newswire May 23, 2025 4:05pm ET Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine by ACCESS Newswire May 21, 2025 7:00am ET Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19 by ACCESS Newswire May 08, 2025 7:00am ET Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 by ACCESS Newswire May 01, 2025 6:30am ET Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates by ACCESS Newswire Apr 10, 2025 7:00am ET Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 by ACCESS Newswire Apr 07, 2025 7:00am ET Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025 by ACCESS Newswire Mar 31, 2025 7:00am ET Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults by ACCESS Newswire Feb 28, 2025 10:30am ET Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine by ACCESS Newswire Feb 25, 2025 7:00am ET Moderna to Present at Upcoming Conferences in March 2025 by ACCESS Newswire Feb 14, 2025 6:28am ET Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates by ACCESS Newswire Jan 29, 2025 7:00am ET Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025 by ACCESS Newswire Jan 24, 2025 6:30am ET Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union by ACCESS Newswire Jan 17, 2025 4:28pm ET Moderna Announces Updates on Pandemic Influenza Program by ACCESS Newswire Jan 13, 2025 7:00am ET Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference by ACCESS Newswire Nov 25, 2024 7:00am ET Moderna to Present at Upcoming Conferences in December 2024 by ACCESS Newswire Nov 03, 2024 12:27pm ET Shareholder Notice to Long-Term Shareholders of Moderna, Inc. (MRNA) by Newsfile Oct 08, 2024 4:00pm ET FINAL MRNA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Moderna, Inc. Investors to Join the Class Action Lawsuit! by Newsfile Oct 08, 2024 3:13pm ET FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna by Newsfile Oct 07, 2024 12:04pm ET Faruqi & Faruqi Reminds Moderna Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA by Newsfile Oct 01, 2024 3:15pm ET MRNA DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action - MRNA by Newsfile Oct 01, 2024 1:44pm ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna by Newsfile Sep 30, 2024 1:24pm ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna by Newsfile Sep 28, 2024 1:01pm ET ROSEN, A TOP-RANKED LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action - MRNA by Newsfile Sep 26, 2024 6:22pm ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna by Newsfile Sep 26, 2024 5:47pm ET ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action - MRNA by Newsfile Sep 25, 2024 5:46pm ET ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action - MRNA by Newsfile Sep 24, 2024 10:06am ET DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna by Newsfile Sep 22, 2024 8:48pm ET ROSEN, LEADING TRIAL ATTORNEYS, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA by Newsfile Sep 21, 2024 7:41pm ET ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA by Newsfile Sep 20, 2024 12:34pm ET ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA by Newsfile Sep 20, 2024 10:47am ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna by Newsfile Sep 18, 2024 6:15pm ET ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA by Newsfile